Published in final edited form as:

Org Lett. 2008 March 20; 10(6): 1111–1114. doi:10.1021/ol7030747.

Synthesis, Pharmacology, and Cell Biology of *sn*-2-Aminooxy Analogues of Lysophosphatidic Acid

Joanna Gajewiak[†], Ryoko Tsukahara[‡], Yuko Fujiwara[‡], Gabor Tigyi[‡], and Glenn D. Prestwich[†]

Glenn D. Prestwich: gprestwich@pharm.utah.edu

[†]Department of Medicinal Chemistry, The University of Utah, 419 Wakara Way, Suite 205, Salt Lake City, Utah, 84108-1257

[‡]Department of Physiology, College of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee 38163

Abstract

An efficient enantioselective synthesis of *sn*-2-aminooxy (AO) analogues of lysophosphatidic acid (LPA) that possess palmitoyl and oleoyl acyl chains is presented. Both *sn*-2-AO LPA analogues are agonists for the LPA₁, LPA₂, and LPA₄ G-protein-coupled receptors, but antagonists for the LPA₃ receptor and inhibitors of autotaxin (ATX). Moreover, both analogues stimulate migration of intestinal epithelial cells in a scratch wound assay.

Lysophosphatidic acid (1- or 2-acyl-*sn*-glycerol 3-phosphate, LPA) is a deceptively simple ligand that elicits a rich palette of biological responses, including platelet aggregation, promotion of cell survival, and cell migration.^{1,2} The most important source of LPA is the action of lysophospholipase D (lysoPLD), or autotaxin (ATX), on lysophosphatidyl choline (LPC).³ ATX is one of the 40 most upregulated genes in invasive cancers⁴ and has been implicated in cell motility and tumor invasion, metastasis, and neovascularization.³ LPA signals through the activation of specific receptors, which in turn leads to distinct cellular events depending on the receptor subtype expressed by the targeted cell. Cell surface LPA receptors belong to the membrane G protein-coupled receptors (GPCRs) protein family, and five mammalian LPA GPCRs have been characterized: LPA₁, LPA₂, LPA₃, LPA₄, and LPA₅.^{1,5–8}

Modification of LPA may involve either the phosphate head group, the glycerol backbone, or the acyl groups, leading to many changes in biological activity.^{9–12} Only a few analogues of LPA feature modifications only at the *sn*-2 position (Figure 1). For example, OMPT (1-oleoyl-2-*O*-methyl-*rac*-glycerophosphothioate), in either the racemic¹³ or optically pure¹⁴ forms, are potent agonists for the LPA₃ receptor. The HE-LPA (hydroxyethoxy-LPA)

analogues¹⁵ are modest agonists for LPA₃ with 10-fold lower potency than the parent oleoyl LPA. Finally, the *sn*-2-F LPA analogs¹⁶ show relatively weak agonist activity for all LPA receptor isoforms.

Recently, series of novel cytotoxic phospholipids, LPA-like serine amide phosphates (SAPs) were synthesized and demonstrated to be low micromolar inhibitors of prostate tumor cell proliferation.¹⁷ The key element of this structure was the presence of a primary amine at the *sn*-2 position. Rather than introduce a strongly basic group into the LPA structure, our approach was to introduce the less basic but strongly nucleophilic aminooxy (AO) group at the *sn*-2 position. AO compounds are frequently employed as potent inhibitors of pyridoxal-5-phosphate-dependent enzymes, such as aminotransferases, serine hydroxymethyltransferase, tyrosine decarboxylase, cystationase, and ornithine decarboxylase, whereby the aminooxy moiety forms a stable oxime with the aldehyde group present on the cofactor.^{18–22} AO analogues have also been demonstrated to function *in vitro* as potent antimalarial agents.²³

We used the Mitsunobu reaction to introduce the AO functionality in stereocontrolled manner using straightforward protection and deprotection steps, thus elaborating an efficient synthetic approach to produce enantiomerically pure *sn*-2 AO-LPA analogues. Herein we describe the asymmetric total syntheses of two *sn*-2-AO LPA analogues, as well as evaluation in pharmacological, biochemical, and cell biological assays that reveal unexpected agonist and antagonist activities.

Synthesis

The synthesis of *sn*-2-AO LPA started with benzylation of (*S*)-solketal (**1**) (Scheme 1), followed by removal of the isopropylidene with an acidic ion-exchange resin,^{24,25} to give intermediate diol **2**. Next, TBDMS was introduced^{26,27} at the primary hydroxyl group at 0–3 °C to produce precursor **3**, which was transformed *via* a Mitsunobu reaction at 0 °C^{28,29} into phthalimide derivative **4** with clean inversion of configuration at the stereogenic center. Hydrazine monohydrate treatment of compound **4**²⁹ afforded the aminooxy intermediate **5** in quantitative yield. The enantiomeric purity of the aminooxy compound was verified by conversion to the (*R*)-Mosher amide;³⁰ ¹⁹F NMR showed that intermediate **5** to have >95% enantiomeric purity. Next, the aminooxy group of **5** was reprotected with Boc to produce derivative **6**, and the benzyl ether was hydrogenolyzed to yield alcohol **7** in over 95% yield. Compound **7** was converted to the palmitoyl (**8a**) and oleoyl (**8b**) esters using carbodiimide chemistry, and deprotection of the silyl ether with Bu₄NF²⁶ in THF smoothly produced intermediates **9a** and **9b** in high yields.

In attempting to remove both methyl and Boc protecting groups, neither an excess of TMSBr nor TMSBr followed by TFA, nor anhydrous HCl gave any desired product. Finally, each ester **11a** and **11b** was treated with BSTFA (*N,O*-bis(trimethylsilyl)trifluoroacetamide)³² and TMSBr for 1 h under strict anhydrous condition in CH₂Cl₂, followed by addition of a wet CH₂Cl₂ (0.5% water) with stirring for 45 min. The crude compounds were then dried *in vacuo*, and 10% aq. methanol was added, which resulted in simultaneous deprotection of Boc group and the phosphate methyl esters. The desired compounds **12a** and **12b** (Scheme 2) were obtained in homogeneous form in good yields after filtration of each methanol solution through a Whatman PTFE Syringe Filter.

Pharmacology of AO-LPA Analogues on LPA Receptors

The pharmacological properties of AO-LPA analogues **12a** and **12b** were evaluated on LPA_{1–3} GPCRs in the McArtl rat hepatoma cell line RH7777, and on LPA₄ in CHO cells.

Table 1 summarizes these data, which show that both palmitoyl and oleoyl *sn*-2-AO LPA analogues are agonists for the LPA₁, LPA₂, and LPA₄ G-protein-coupled receptors but are antagonists for the LPA₃ receptor. The oleoyl analogue **12b** is the most potent (382 nM) and also a full agonist for LPA₂. This analogue is also the most potent (56 nM) partial antagonist for LPA₃. Both **12a** and **12b** inhibit recombinant ATX activity at 10 μM with potencies similar to those of LPA itself (see Supporting information).

Activity of AO-LPA Analogues on Cell Migration

The AO-LPA analogues **12a** and **12b** enhanced rate cell migration in IEC-6 human intestinal endothelial cells in a scratch wound assay (Figure 2). In this assay, the rate of cell migration is measured by the time it takes for the cells to close a gap in the cell monolayer created by “scratching” the monolayer with a pipet tip. This effect is congruent with the agonist activity toward the LPA₂ receptor, which is coupled to the Rho/Rac1 small GTPases and augments cell migration and cell survival.³³

The replacement of the *sn*-2 hydroxy group of LPA with the more nucleophilic aminooxy function afforded AO-LPA analogues **12a** and **12b**. This small structural change has profound effects on the receptor pharmacology and cell biology of the analogues. Instead of the pan-receptor agonist activity exhibited by LPA, **12a** and **12b** are weak agonists for LPA₁ and LPA₄, strong agonists for LPA₂, and antagonists for the LPA₃. This mixed profile isoform selectivity makes them useful research tools for cell biology. Moreover, their ability to enhance migration of intestinal epithelial cells *in vitro* suggests therapeutic potential for repair of the gastrointestinal epithelium *in vivo*.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported by the National Institutes of Health (NS29632 to G.D.P. and HL61469 and CA921160 to G.T.)

References

1. Mills GB, Moolenaar WH. Nat. Rev. Cancer. 2003; 3:582–591. [PubMed: 12894246]
2. Feng L, Mills GB, Prestwich GD. Expert Opin. Ther. Pat. 2003; 13:1619–1634.
3. Hama K, Aoki J, Fukaya M, Kishi Y, Sakai T, Suzuki R, Ohta H, Yamori T, Watanabe M, Chun J, Arai H. J. Biol. Chem. 2004; 279:17634–17639. [PubMed: 14744855]
4. Euer N, Schwirzke M, Evtimova V, Burscher, Jarsch M, Tarin D, Weidle U. Anticancer Res. 2002; 22:733–740. [PubMed: 12014644]
5. Kotarsky K, Boketoft Å, Bristulf J, Nilsson NE, Norberg Å, Hansson S, Owman C, Sillard R, Leeb-Lundberg LMF, Olde B. J. Pharmacol. Exp. Ther. 2006; 318:619–628. [PubMed: 16651401]
6. Luquain C, Sciorra V, Morris A. TIBS. 2003; 28:377–383. [PubMed: 12878005]
7. Noguchi K, Ishii S, Shimizu T. J. Biol. Chem. 2003; 278:25600–25606. [PubMed: 12724320]
8. Umezu-Goto M, Tanyi J, Lahad J, Liu S, Yu S, Lapushin R, Hasegawa Y, Lu Y, Trost R, Bevers T, Jonasch E, Aldape K, Liu J, James RD, Ferguson CG, Xu Y, Prestwich GD, Mills GB. J. Cell. Biochem. 2004; 92:1115–1140. [PubMed: 15258897]
9. Jiang G, Xu Y, Fujiwara Y, Tsukahara T, Tsukahara R, Gajewiak J, Tigyi G, Prestwich GD. ChemMedChem. 2007; 2:679–690. [PubMed: 17443831]
10. Xu Y, Aoki J, Shimizu K, Umezu-Goto M, Hama K, Takanezawa Y, Yu S, Mills GB, Arai H, Qian L, Prestwich GD. J. Med. Chem. 2005; 48:3319–3327. [PubMed: 15857137]

11. Prestwich GD, Xu Y, Qian L, Gajewiak J, Jiang G. *Biochem. Soc. Trans.* 2005; 33:1357–1361. [PubMed: 16246118]
12. Gajewiak J, Tsukahara R, Tsukahara T, Fujiwara Y, Yu S, Lu Y, Mills GB, Tigyi G, Prestwich GD. *Chem. Med. Chem.* 2007; 2:1789–1798. [PubMed: 17952880]
13. Hasegawa Y, Erickson JR, Goddard GJ, Yu S, Liu S, Cheng KW, Eder A, Bandoh K, Aoki J, Jarosz R, Schrier AD, Lynch KR, Mills GB, Fang X. *J. Biol. Chem.* 2003; 278:11962–11969. [PubMed: 12554733]
14. Qian L, Xu Y, Hasegawa Y, Aoki J, Mills GB, Prestwich GD. *J. Med. Chem.* 2003; 46:5575–5578. [PubMed: 14667211]
15. Qian L, Xu Y, Arai H, Aoki J, McIntyre TM, Prestwich GD. *Org. Lett.* 2003; 5:4685–4688. [PubMed: 14627415]
16. Xu Y, Qian L, Prestwich GD. *J. Org. Chem.* 2003; 68:5320–5330. [PubMed: 12816494]
17. Gududuru V, Hurh E, Durgam GG, Hong SS, Sardar VM, Xu H, Dalton JT, Miller DD. *Bioorg. Med. Chem. Lett.* 2004; 14:4919–4923. [PubMed: 15341952]
18. Baskaran N, Prakash V, Savithri HS, Radhakrishnan AN, Appaji Rao N. *Biochemistry.* 1989; 28:9613–9617. [PubMed: 2611250]
19. Beeler T, Churchich JE. *J. Biol. Chem.* 1976; 251:5267–5271. [PubMed: 8458]
20. Rosenthal GA. *Eur. J. Biochem.* 1981; 114:301–304. [PubMed: 7215357]
21. Rosenthal GA. *Life Sci.* 1997; 60:1635–1641. [PubMed: 9129118]
22. Worthen DR, Ratliff DK, Rosenthal GA, Trifonov L, Crooks PA. *Chem. Res. Toxicol.* 1996; 9:1293–1297. [PubMed: 8951231]
23. Berger B. *Antimicrob. Agents Chemother.* 2000; 44:2540–2542. [PubMed: 10952611]
24. Ryan M, Smith MP, Vinod TK, Lau WL, Keana JFW, Griffith OH. *J. Med. Chem.* 1996; 39:4366–4376. [PubMed: 8893831]
25. Heeb NV, Nambiar KP. *Tetrahedron Lett.* 1993; 34:6193–6196.
26. Corey EJ, Venkateswarlu A. *J. Am. Chem. Soc.* 1972; 94:6190–6191.
27. Zhang D, Poulter CD. *J. Am. Chem. Soc.* 1993; 115:1270–1277.
28. Mitsunobu O, Wada M, Sano T. *J. Am. Chem. Soc.* 1972; 94:679–680.
29. Bailey S, Harnden MR, Jarvest RL, Parkin A, Boyd MR. *J. Med. Chem.* 1991; 34:57–65. [PubMed: 1846922]
30. Dale JA, Dull DL, Mosher HS. *J. Org. Chem.* 1969; 34:2543–2549.
31. Carpino LA, Giza CA, Carpino BA. *J. Am. Chem. Soc.* 1959; 81:955–957.
32. Erickson, JR. United States Patent. 6,380,177. 2002.
33. Deng W, Shuyu E, Tsukahara R, Valentine W, Durgam G, Gududuru V, Balazs L, Manickam B, Arsura M, Vanmiddlesworth L, Johnson L, Parrill A, Miller D, Tigyi G. *Gastroenterology.* 2007; 132:1834–1851. [PubMed: 17484878]

Figure 1.
Structures of LPA, OMPT, HE-LPA, and SAP.

Migration of IEC-6 cells with LPA or with 12a and 12b

Figure 2.

Compounds **12a** and **12b** promote cell migration in a scratch wound assay using IEC-6 cells. The basal rate of cell motility was measured in the presence of 0.1% BSA vehicle for stabilizing the LPA or LPA analogue, and the maximal LPA-induced response was evoked by treatment with 100 nM LPA. The bars represent the mean rate of cell migration in scratch wounds treated with different concentrations of **12a** and **12b**. The results represent the rate of migration over an 8 h period and the mean of 8 experiments.

Scheme 1.
 Synthesis of *sn*-2-AO-LPA Intermediates **9a** and **9b**

Scheme 2. Conversion of Intermediates to *sn*-2-AO-LPA Analogues **12a** and **12b**

Table 1

Pharmacological Characterization of **12a** and **12b** in LPA GPCR Assays

compd	LPA ₁		LPA ₂		LPA ₃		LPA ₄	
	EC ₅₀ [nM] (E _{max}) ^a	IC ₅₀ [nM] (Inhib. %) ^b	EC ₅₀ [nM] (E _{max}) ^a	IC ₅₀ [nM] (Inhib. %)	EC ₅₀ [nM] (E _{max}) ^a	IC ₅₀ [nM] (Inhib. %)	EC ₅₀ [nM] (E _{max}) ^a	IC ₅₀ [nM] (Inhib. %)
12a	>4630 (57.3)	NE ^c	2450 (68.8)	NE	NE	2670 (63.1)	>10800 (45.8)	NE
12b	>7440 (51.2)	NE	382 (104)	NE	NE	56 (45.9)	1880 (86.8)	NE

^a E_{max} = maximal efficacy of compound/maximal efficacy of LPA 18:1 × 100.^b Inhib. % = % maximal inhibition of the response to 200 nM LPA 18:1^c NE = no effect was shown at the highest concentration (30 μM) tested.